Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial.

Goodin DS, Reder AT, Ebers GC, Cutter G, Kremenchutzky M, Oger J, Langdon D, Rametta M, Beckmann K, Desimone TM, et al.